United States · 
What does Sanderling Ventures invest in?
Sanderling Ventures invests most often at Series C and Series B (48% of the rounds on record), in sectors such as Biomedical, Small Molecule Therapeutics and Biologics.
Sanderling Ventures highlights
- 01
64 rounds on record
- 02
Mostly Series C and Series B: 48% of its rounds
- 03
Sole investor in 8 rounds, median $4.0M
- 04
5 exits from the portfolio
What they do
Dedicated to early-stage biomedical financing and active managementFrom their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- BiomedicalSmall Molecule TherapeuticsBiologics
- Based in
- San Mateo, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first64 appearances
- 2019
1 round
- Aug
- 2018
1 round
- Nov
- 2017
2 rounds
- Nov
- Jul
- 2015
1 round
- Jan
- 2013
3 rounds
- Dec
- Jul
- Feb
- 2012
2 rounds
- Sept
- Apr
- 2011
4 rounds
- Dec
- Nov
- Feb
- Jan
- 2010
8 rounds
- Oct
- Aug
- Aug
- Jul
- Apr
- Apr
- Jan
- Jan
- 2009
5 rounds
- Dec
- Nov
- Aug
- Jan
- Jan
- 2008
8 rounds
- Dec
- Jul
- Jun
- Jun
- Mar
- Mar
- Feb
- Jan
- 2007
8 rounds
- Nov
- Jul
- Jul
- Jul
- May
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration5 named
FAFred A. MiddletonManaging Director of the General PartneriFiling they signed
FAFrederick Alexander MiddletonManaging DirectoriForm ADV
PCPeter C.M. McWilliamsManaging Director of the General PartneriFiling they signed
RGRobert G. McNeilManaging Director of the General PartneriFiling they signed
TCTimothy Curtis MillsManaging Director of the General PartneriFiling they signed
We also hold 13 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$161Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Sanderling Management Company, LLC
- SEC number
- CRD 162520
What they claim to have backed
From their own portfolio page (on their website)
14 of 41 we have independently watched raise
Altor BioScienceAsteresCalciMedicaCardionetCyleneEndocyteGlycomineLineaGenMetaventionNaviscanSoterawirelessStereotaxisTheravidaViaCyteActimisAderisAdvanced CardiovascularArtielleBioSpaceCarecentricDalcorpharmaDendreonDepoTechDigiradGeminXISTAInterMuneKadmusLiphorusNeoMendPaciraPulsarRegeneronStentorTaligenTheregenTherilliaToraxVentritexVicalXoma
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed5 in all
InfraReDxBought by Nipro CorporationUndisclosedOct 2015
NeomendBought by C. R. Bard$140MOct 2012
Gemin X PharmaceuticalsBought by Cephalon$525MMar 2011
Taligen TherapeuticsBought by Alexion Pharmaceuticals$111MJan 2011
Actimis PharmaceuticalsBought by Boehringer Ingelheim$515MJun 2008
An exit counts when it came after the firm's first round in the company. From historical deal records.